At present, a lot of novel aurora kinase inhibitors only have effects on aurora A, such as MLN-8237, which has been found to promote the apoptosis and autophagy of breast cancer cells by regulating the p38 MAPK/Akt/mTOR pathway and has entered the second phase of clinical trials. This evidence concerns the gene MTOR and breast carcinoma.